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Abstract Metastases are the most common malignancies
involving bone; breast, prostate, lung and thyroid are the
main sites of primary cancer. However, up to 30 % of
patients present with bone metastases of unknown origin,
where the site of the primary neoplasm cannot be identified
at the time of diagnosis despite a thorough history, physical
examination, appropriate laboratory testing and modern
imaging technology (CT, MRI, PET). Sometimes only
extensive histopathological investigations on bone speci-
mens from biopsy can suggest the primary malignancy. At
other times, a bone lesion can have such a highly undif-
ferentiated histological appearance that a precise patho-
logical classification on routine hematoxylin–eosin-stained
section is not possible. The authors reviewed the relevant
literature in an attempt to investigate the epidemiology of
the histological primaries finally identified in patients with
bone metastases from occult cancer, and a strategy of
management and treatment of bone metastases from occult
carcinomas is suggested. Lung, liver, pancreas and gas-
trointestinal tract are common sites for primary occult tu-
mors. Adenocarcinoma is the main histological type,
accounting for 70 % of all cases, while undifferentiated
cancer accounts for 20 %. Over the past 30 years, lung
cancer is the main causative occult primary for bone
metastases and has a poor prognosis with an average sur-
vival of 4–8 months. Most relevant literature focuses on
the need for standardized diagnostic workup, as surgery for
bone lesions should be aggressive only when they are
solitary and/or the occult primaries have a good prognosis;
in these cases, identification of the primary tumor may be
important and warrants special diagnostic efforts. Howev-
er, in most cases, the primary site remains unknown, even
after autopsy. Thus, orthopedic surgery has a mainly pal-
liative role in preventing or stabilizing pathological frac-
tures, relieving pain and facilitating the care of the patient
in an attempt to provide the most appropriate therapy for
the primary tumor as soon as possible.
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Introduction
Metastases are the most common type of malignant tumor
involving bone; the skeleton is the third most frequent site
for metastatic carcinoma after the lung and liver. Any
malignant tumor may metastasize to bone: the most com-
mon malignancies are breast in women and prostate in men
but secondary lesions from lung cancer have risen in both
sexes in the last two decades [1–4]. Skeletal lesions can be
the first manifestation of malignancy in 25–30 % of cases
[4–6]. In recent years, imaging studies have improved, the
use of chest and abdominal computed tomography (CT) is
increasing and diagnostic endoscopic techniques have ad-
vanced; new tumor markers have been identified, guided
percutaneous bone biopsy has gained widespread
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acceptance, immunohistochemistry and even chromosomal
analysis have been developed for studying histological
specimens so that the primary malignancy is most often
identified at an early stage [1, 4, 5, 7, 8]. However, among
patients with bone metastases, 22.6–30 % have no evi-
dence of the primary tumor at presentation [2, 8–12]. In
fact, unknown primary malignancy is not a well-defined
disease entity. On the one hand, it can be considered as a
variety of different malignant and metastatic tumors with
an occult source at initial presentation. Thus, the initial
medical histories, physical examinations and routine
laboratory tests fail to detect the site of the primary neo-
plasm as it is too small and dormant or it has disappeared
[13]. In these cases, the histological findings such as im-
munohistochemical and other morphological parameters
from the bone biopsy can be diagnostic. On the other hand,
a bone lesion can have such a highly undifferentiated his-
tological appearance that a precise pathological classifica-
tion on routine hematoxylin–eosin-stained section is not
possible [11, 14, 15].
As a consequence, screening and early diagnosis are im-
possible by definition. The lack of a detectable primary
neoplasm delays staging, treatment is challenging, and
prognosis and outcome can be uncertain. In any case, even
when the primary cancer is unknown, the patient should al-
ways be referred as soon as possible to an oncologist after the
diagnosis of bone metastasis has been confirmed at biopsy.
Epidemiology
Metastasis of unknown primary origin is reported to occur in
3–4 % of all cancer patients and 10–15 % of them present
with skeletal localizations [2, 13, 16, 17]. The bone is the
third most common site of metastatic cancer of unknown
primary origin, after the lymph nodes and the lung [12, 17].
Lung, liver, pancreas and gastrointestinal tract are common
sites of primary occult tumors. Adenocarcinoma is the main
histological type, accounting for 70 % of all cases, while
undifferentiated cancer accounts for 15 %and squamous cell
carcinomas 10 % [12, 13]. Occult carcinomas are clinically
different from their respectivemanifest forms: with regard to
skeletal involvement, the incidence of bone metastases from
pulmonary carcinoma is much lower if the primary is occult
(4 %) than if it is known (30–50 %); similarly, bone lesions
from occult prostate cancer are three times less common than
from a known primary, whereas they are four times more
common in cases of occult pancreatic primary [12]. Some
unknown primary tumors are treatable, like lymphoma, ex-
tragonal germ cell neoplasms and ovarian cancer, but the
majority of cases have a short fatal clinical course with very
scarce possibilities of employing effective chemotherapy
[12, 16, 18].
We reviewed the relevant literature in an attempt to in-
vestigate the epidemiology of the histological primaries fi-
nally identified in patients with bone metastases from occult
cancer (Table 1). Since from the end of the 1980s, lung
carcinomawas suggested to be themost commonly causative
histotype of metastatic bone disease from occult primaries
[2, 5, 11, 19–21]. Rougraff et al. [19] described a retro-
spective analysis of diagnostic workups in 40 patients: lung
cancers accounted for 63 % of the identified primaries.
Nottebaert et al. [2] found lung carcinomas to be responsible
for 52 % of 51 cases of bone lesions from unknown origin,
while they accounted for only 7 % of bone metastases with a
diagnosed primary. Moreover, patients with skeletal metas-
tases from occult carcinomas showed a high incidence of
spinal metastases, cord compression and pathological frac-
tures and a significantly shorter survival compared to bone
lesions secondary to known primaries. Over 10 years later,
Shih et al. [11] reported similar demographic data (incidence
30 %, male sex and lung prevalence), intractable pain as the
predominant symptom, lytic appearance at radiography and
poor prognosis. From an analysis of the Swedish Cancer
Registry from 1993 to 2008, Hemminki et al. [13] found that
patients with metastases from unknown origin diagnosed in
the bone mostly died of lung cancer. Vandecandelarae et al.
[1] investigated epidemiological changes from the middle of
the last century to recent times: a marked increase in lung
cancer was noted in all these patients over the last 40 years,
especially among women as an obvious demographic effect
of smoking; occult breast and prostate cancer reduced their
incidence thanks to advances in diagnosis and treatment at an
early stage [1]. Among patients admitted in recent years for
bone metastases, different authors surprisingly reported an
increased incidence of unidentified primaries despite the
improvements in diagnostic examinations, new tumor
markers, immunohistochemical methods and guided percu-
taneous biopsy techniques over a 30-year period [1, 5, 22].
Vandecandelarae et al. [1] compared two series of patients
with bone metastases from the same rheumatology depart-
ment, one extending from 1958 to 1967 and the other from
1989 to 1996. Investigations looking for a primary were
negative in 9/34 (27 %) patients in the early series and 36/95
(38 %) patients in the recent series. However, these datamay
reflect the less effective diagnostic and treatment options
available in rheumatological institutes, whereas specialized
cancer centers now offer many sophisticated diagnostic
procedures and valuable therapeutic protocols that can even
be performed on an outpatient basis.
Thus, detection of bone metastases from occult pri-
maries should raise the suspicion that the lungs are the
tissue of origin and the suspicion should be stronger in
relatively young patients (60–65 years) [1, 13]. After pul-
monary origin, bone metastases from undiagnosed renal
clear cell carcinomas have increased to 12 %, more than
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prostate at 10 %, whereas occult thyroid carcinomas are
extremely rare (3 %) [1].
As the spine is the most common site of bone metas-
tases, it is also reported to be the most common site of
lesions of unknown origin, followed by the pelvis and long
bones; lung and thyroid carcinomas should be strongly
suspected at this location [21, 23]. However, spinal ma-
lignancy of unknown origin is often derived not only from
solid tumors, but also from hematological tumors [1, 21,
24, 25]. In the series reported by Iizuka et al. [25],
myeloma was the most common etiology (22 %), followed
by lung carcinoma, prostate carcinoma and lymphoma.
Serological evaluation for monoclonal gammopathy was
very useful in revealing the diagnosis of myeloma in all
affected patients.
Acrometastases are extremely unusual (\0.1 %), espe-
cially as the first presentation of occult carcinoma, but
strongly suggest bronchogenic or gastrointestinal cancer [3,
26, 27].
Strategy of diagnosis and treatment
In patients affected by bone metastases of unknown origin,
one of the most important prognostic and treatment-
conditioning factors is the histological type, and therefore
biopsy is mandatory in an attempt to detect the primary
cancer [6, 28, 29]. Biopsy should be performed in the most
accessible osseous or concomitant visceral lesion [19, 20,
24] and should include histochemistry, immunohistology
and electron microscopy; thus, the surgeon should obtain
sufficient material to enable study with special stains,
estrogen receptor activity, and hormonal and tumor mark-
ers [30]. Bone biopsy is a key component of the diagnostic
strategy and histological confirmation is particularly valu-
able in patients who have a solitary bone metastasis or
unusual radiological features suggesting a myeloma or a
sarcoma rather than a carcinoma. Although histological
studies rarely identify the exact nature of the primary, they
often provide important diagnostic clues: highly suggestive
histological patterns may be found in small-cell lung can-
cer, clear-cell renal cancer, or well-differentiated thyroid
carcinoma. Immunohistochemistry helps to determine the
nature of the primary, most notably when differentiation is
minimal. However, Rougraff et al. [19] reported that
biopsy alone was unable to identify the primary site of the
malignant tumor in 60 % of cases.
Whole-body bone scintigraphy or positron emission to-
mography (PET)-CT scan, plain radiographs of painful
bones and chest–abdominal–pelvic CT are always





Main PC PC in order of frequency Occult PC
Simon and Karluk [14] 12 6 Kidney 3 (50 %) Kidney (3), lung (2), others (1) 6 (50 %)
Simon and Bartucci [31] 46 20 Lung 7 (35 %) Lung (7), kidney (6), breast = prostate (2),
ovarian = thyroid = liver (1)
26 (56 %)
Nottebaert et al. [2] 51 33 Lung 17 (51 %) Lung (17), others (16) 18 (35 %)
Shih et al. [11] 52 28 Lung 9 (32 %) Lung (9), liver (8), kidney (5), prostate (3),
thyroid (2), rectum (1)
24 (46 %)
Rougraff et al. [19] 40 34 Lung 23 (67 %) Lung (23), kidney (4), breast = colon = liver =
bladder (1), others (3)
6 (15 %)
Jacobsen et al. [20] 29 24 Lung 11 (46 %) Lung (11), prostate (3), breast = lymphomas (2),
kidney = ovary = pancreas = stomach = small
intestine carcinoid = retroperitoneal
rhabdomyosarcoma (1)
5 (17 %)
Katagiri et al. [5] 64 59 Lung 23 (39 %) Lung (23), prostate (11), breast = liver (5), others (15) 5 (8 %)
Vandecandelaere et al. [1] 129 84 Lung 36 (43 %) Lung (36), prostate (17), kidney (15), breast (9),
stomach (2), bladder = colon = testis =
pancreas = liver (1)
45 (35 %)
Destombe et al. [24] 107 94 Lung 37 (39 %) Lung (37), prostate (26), breast (20), bladder (11) 13 (12 %)
Iizuka et al. [25] 27 26 Myeloma 7
(27 %)
Myeloma (7), lymphoma (3), lung (6), prostate (4),
kidney = thyroid = liver = pancreas =
stomach = esophagus (1)
1 (4 %)
Hemminki et al. [13] 501 256 Lung 128 (50 %) Lung (128), urinary (29), prostate (16), breast (14),
colon (12), pancreas = gastrointestinal (10), liver (9),
biliary system (4), stomach (3), mediastinum (2),
ovarian (1), others (18)
203 (40 %)
BMUO bone metastases of unknown origin, PC primary carcinoma
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recommended when occult carcinoma presents with
skeletal location regardless of gender. In men, prostate-
specific antigen (PSA) levels should be investigated first. In
women, mammography is indicated when appropriate im-
munohistochemistry confirms breast origin; if the mam-
mogram is non-diagnostic and there is histopathological
evidence of breast cancer, breast ultrasound and/or mag-
netic resonance imaging (MRI) should be suggested [31].
Serum protein electrophoresis should be performed as an
initial routine study in patients with incidental spinal
metastasis [25]. With regard to skeletal findings, the ra-
diographic appearance of the bone lesions is a valuable
clue for suggesting the primary; bone CT and MRI are
generally used as complementary techniques to confirm the
presence of the metastases and to characterize them [3, 6,
12, 18]. Osteolytic lesions typically result from myeloma,
renal cell cancer, gastrointestinal tract cancer and me-
lanoma. Osteoblastic metastases can occur from prostate
cancer and bronchial carcinoid. The mixed type of metas-
tasis may be seen with breast, lung and cervical cancer.
Other morphological features can aid in assessing the
source of malignant neoplasms: for example, an expansive
and septated metastasis would strongly suggest primary
renal cell cancer or thyroid cancer, while intralesional
calcifications would suggest a mucinous tumor [3]. Highly
hemorrhagic lesions are mostly related to hypernephroma,
thyroid cancer and hepatocellular carcinoma [6]. Serum/
urine immunofixation and osteomedullary biopsy are ad-
vised in the presence of lytic lesions; PSA and thy-
roglobulin levels are mostly recommended for osteoblastic
metastases [12, 18]. Lung tumors can be detected by
modern imaging techniques, including PET-CT scan or
high resolution spiral CT. However, the sensitivity is low
for tumors smaller than 1 cm [13].
On the basis of histology and/or organ-specific clinical
symptoms, further diagnostic workup includes abdominal
and pelvic ultrasound, bronchoscopy, gastric and intestinal
endoscopy, intravenous urography, laparotomy and further
site-specific tumor markers. Due to the overall poor prog-
nosis, too many tests to identify the primary at all costs
may be inappropriate. If these investigations fail to reveal
the primary site, it is unlikely that it will be identified with
further extensive diagnostic procedures, but is then mostly
established at autopsy [2, 17, 30–32].
The mean survival of these patients has not changed in
the last 30 years, ranging from 3 to 12 months from diag-
nosis [2, 11, 16, 20, 31]. In general, unfavorable prognostic
factors for occult primary tumors are male gender, patho-
logical diagnosis of adenocarcinoma and involvement of
multiple organs, besides bone dissemination [12, 31]. In
terms of histology of primary cancer, lung adversely influ-
enced survival rate, whereas breast and myeloma are fa-
vorable [4, 6, 16, 28, 29]. The lung is reported to be the most
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Fig. 1 Schematic indications for treatment of patients with bone metastases from occult primary tumor
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of only 3 months, whereas breast and prostate cancer sur-
vival is relatively favorable at 15 and 23 months, respec-
tively [12, 13, 16, 18, 29, 31, 32]. Patients with a favorable
prognosis include men with blastic bone metastases from
occult adenocarcinoma and elevated PSA and patients with a
single, small and potentially resectable tumor [12, 18, 31].
Probably because of the rarity of occult cancer series
and the short survival of bone metastatic patients in gen-
eral, most of the literature on bone metastases from occult
cancer focuses more on the need for a standardized diag-
nostic flowchart to detect the primary early rather than on a
consensus about clinical management when the primary
remains undiagnosed [1, 2, 5, 17, 19–21, 25, 32]. Mul-
tidisciplinary treatment should attempt to provide local and
systemic tumor control in any case; as unknown origin is
correlated with a short life expectancy, chemo-radiotherapy
and surgery usually have only a palliative role [6, 29].
However, some integrated treatment protocols are poten-
tially curative in a minority of favorable primary diagnoses
[12, 18]. In according with current recommendations and
guidelines [6, 12, 16, 18, 31, 33], we suggest a flowchart of
therapeutic strategy: this approach depends on histological
features, patients’ performance status and survival esti-
mation (Fig. 1). The foremost aims of surgery are to pre-
serve the function of the affected bone, to prevent or
stabilize pathological fractures, and to relieve pain and
facilitate care of the patient while keeping hospitalization
as short as possible. Obviously, anatomical site, multiple
lesions, visceral involvement and performance status in-
fluence surgical options for bone metastases from occult
cancer similarly to those of known origin; however, it is
especially for bone metastases from unknown primaries
that the principle of the more effective and feasible surgical
procedures with the lowest rate of complications should be
maintained [6, 28, 29, 33]. In the near future, further re-
search on staging examinations, immunohistochemistry,
hormone receptor staining and tumor markers may aid in
understanding occult tumor characteristics and lead to the
most appropriate therapies on an individual basis.
In conclusion, the epidemiology from analysis of the
recent literature justifies firstly considering the lungs as the
most probable site of primary carcinoma at the onset of
bone metastases of undetected origin. The main goal of
histology is to identify those primaries for which curative
treatment may be available. Efforts should be made to
identify the primary and to provide radical treatment in
patients who have only one bone metastasis.
Conflict of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Vandecandelaere M, Flipo RM, Cortet B, Catanzariti L,
Duquesnoy B, Delcambre B (2004) Bone metastases revealing
primary tumors. Comparison of two series separated by 30 years.
Jt Bone Spine 71(3):224–229
2. Nottebaert M, Exner GU, von Hochstetter AR, Schreiber A
(1989) Metastatic bone disease from occult carcinoma: a profile.
Int Orthop 13(2):119–123
3. Cooke KS, Kirpekar M, Abiri MM, Shreefter C (1997) US case of
the day. Skeletal metastasis from poorly differentiated carcinoma
of unknown origin. Radiographics 17(2):542–544
4. Piccioli A (2014) Breast cancer bone metastases: an orthopedic
emergency. J Orthopaed Traumatol 15(2):143–144
5. Katagiri H, Takahashi M, Inagaki J, Sugiura H, Ito S, Iwata H
(1999) Determining the site of the primary cancer in patients with
skeletal metastasis of unknown origin: a retrospective study.
Cancer 86(3):533–537
6. Piccioli A, Capanna R (2008) Il trattamento delle metastasi ossee.
Linee Guida S.I.O.T
7. Wedin R, Bauer HC, Skoog L, So¨derlund V, Tani E (2000)
Cytological diagnosis of skeletal lesions. Fine-needle aspiration
biopsy in 110 tumours. J Bone Jt Surg Br 82(5):673–678
8. Xu DL, Zhang XT, Wang GH, Li FB, Hu JY (2005) Clinical
features of pathologically confirmed metastatic bone tumors—a
report of 390 cases. Ai Zheng 24(11):1404
9. Conroy T, Platini C, Troufleau P, Dartois D, Lupors IE, Malissard
L et al (1993) Presentation clinique et facteurspronostics au di-
agnostic de metastases osseuses. A propos de d’uneserie de 578
observations. Bull Cancer 80:S16e22
10. Papagelopoulos P, Savvidou O, Galanis E et al (2009) Advances
and challenges in diagnosis and management of skeletal metas-
tases. Orthopedics 29(7):609–620
11. Shih LY, Chen TH, Lo WH (1992) Skeletal metastasis from
occult carcinoma. J Surg Oncol 51(2):109–113
12. Airoldi G (2012) Cancer of unknown primary origin: utility and
futility in clinical practice. Ital J Med 6:315–326
13. Hemminki K, Riihima¨ki M, Sundquist K, Hemminki A (2013)
Site-specific survival rates for cancer of unknown primary
according to location of metastases. Int J Cancer 133(1):
182–189
14. Simon MA, Karluk MB (1982) Skeletal metastases of unknown
origin. Diagnostic strategy for orthopedic surgeons. Clin Orthop
Relat Res 166:96–103
15. Bitran JD, Ultmann JE (1992) Malignancies of undetermined
primary origin. Dis Mon 38(4):213–260
16. Schwartz H.S. (2008) Metastatic bone disease: diagnosis, eval-
uation and treatment. In: AAOS 2008, 75 h Annual Meeting In-
structional Course Lecture Handout, pp 19–22 (Course n 386)
17. Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G,
Spielmann M, Rouesse J (1988) Early metastatic cancer of unknown
primary origin at presentation. A clinical study of 302 consecutive
autopsied patients. Arch Intern Med 148(9):2035–2039
18. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA (2003) Diag-
nostic and therapeutic management of cancer of an unknown
primary. Eur J Cancer 39(14):1990–2005
19. Rougraff BT, Kneisl JS, Simon MA (1993) Skeletal metastases of
unknown origin. A prospective study of a diagnostic strategy.
J Bone Jt Surg Am 75(9):1276–1281
20. Jacobsen S, Stephensen SL, Paaske BP, Lie PG, Lausten GS
(1997) Skeletal metastases of unknown origin: a retrospective
analysis of 29 cases. Acta Orthop Belg 63(1):15–22
21. Ugras N, Yalcinkaya U, Akesen B, Kanat O (2014) Solitary
bone metastases of unknown origin. Acta Orthop Belg
80(1):139–143
J Orthopaed Traumatol (2015) 16:81–86 85
123
22. Maillefert JF, Tebib J, Huguenin MC, Chauffert B, Pascaud F,
Peere T et al (1993) Les metastases osseuses re´ve´latrices:
recherche du cancer primitif. Sem Hoˆp Paris 69:372–378
23. Khan MN, Sharfuzzaman A, Mostafa MG (2014) Spinal cord
compression as initial presentation of metastatic occult follicular
thyroid carcinoma. J Neurosci Rural Pract 5(2):155–159
24. Destombe C, Botton E, Le Gal G, Roudaut A, Jousse-Joulin S,
Devauchelle-Pensec V, Saraux A (2007) Investigations for bone
metastasis from an unknown primary. Jt Bone Spine 74(1):85–89
Epub 2006 Nov 30
25. Iizuka Y, Iizuka H, Tsutsumi S, Nakagawa Y, Nakajima T,
Sorimachi Y, Ara T, Nishinome M, Seki T, Takagishi K (2009)
Diagnosis of a previously unidentified primary site in patients
with spinal metastasis: diagnostic usefulness of laboratory ana-
lysis, CT scanning and CT-guided biopsy. Eur Spine J
18(10):1431–1435
26. Wijayaratna R, Ng JW (2013) Metatarsal metastasis as the pre-
senting feature of occult colorectal carcinoma. BMJ Case Rep
27. van Veenendaal LM, de Klerk G, van der Velde D (2014) A
painful finger as first sign of a malignancy. Geriatr Orthop Surg
Rehabil 5(1):18–20
28. Piccioli A, Rossi B, Scaramuzzo L, Spinelli MS, Yang Z, Mac-
cauro G (2014) Intramedullary nailing for treatment of pathologic
femoral fractures due to metastases. Injury 45(2):412–417
29. Forsberg JA, Eberhardt J, Boland PJ, Wedin R, Healey JH (2011)
Estimating survival in patients with operable skeletal metastases:
an application of a bayesian belief network. PLoS One
6(5):e19956
30. Perchalski JE, Hall KL, Dewar MA (1992) Metastasis of un-
known origin. Prim Care 19(4):747–757
31. Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM,
Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease
GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L,
Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varad-
hachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass
DA (2014) Occult primary, version 3.2014. NCCN guidelines.
J Natl Compr Cancer Netw 12(7):969–974
32. Simon MA, Bartucci EJ (1986) The search for the primary tumor
in patients with skeletal metastases of unknown origin. Cancer
58(5):1088–1095
33. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE,
McFadden ET, Carbone PP (1982) Toxicity and response criteria
of the Eastern Cooperative Oncology Group. Am J Clin Oncol
5:649–655
86 J Orthopaed Traumatol (2015) 16:81–86
123
